11:23 PM EST, 11/10/2026 (MT Newswires) -- Merck KGaA (MRK.F) received US Food and Drug Administration approval for Pimjetmi to treat adults with symptomatic tenosynovial giant cell tumor. The German science and technology company said Tuesday the oral drug, also known as pimicotinib, is indicated as a once-daily treatment for US patients with the rare, locally aggressive tumor occurring in or around the joints, where surgery could cause worsening functional limitations or severe complications. The decision was based on positive results from the ongoing phase 3 Maneuver trial, in which Pimjetmi showed "early and durable" tumor response. The company previously received approval for Pimjetmi in China, Canada, and Switzerland.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.